Tempus AI Teams Up With Renalytix to Boost Adoption of Prognostic Blood Test for Kidney Disease

MT Newswires Live

Sep 15, 2025

Tempus AI (TEM) has formed a partnership with Renalytix to boost adoption of the kidneyintelX.dkd prognostic blood test for eligible patients who have type 2 diabetes with chronic kidney disease, Renalytix said Monday.

Renalytix said its kidneyintelX.dkd will be the first chronic kidney disease test in Tempus' portfolio, designed for use in risk prediction for progressive kidney function decline in type 2 diabetes patients with chronic kidney disease stages 1-3b.

The tests will be processed at a Renalytix laboratory and the tests' insights will be used for making changes in patient management, potentially helping healthcare providers improve key metrics in diabetes and kidney care and mitigate kidney function decline, the company said.

Tempus AI shares were up nearly 2% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2567149401"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567149401\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567149401?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567149401","market":"sh","top_or_hot":-1,"title":"Tempus AI Teams Up With Renalytix to Boost Adoption of Prognostic Blood Test for Kidney Disease","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) has formed a partnership with Renalytix to boost adoption of the kidneyintelX.dkd prognostic blood test for eligible patients who have type 2 diabetes with chronic kidney disease, Renalytix said Monday.</p><p>Renalytix said its kidneyintelX.dkd will be the first chronic kidney disease test in Tempus' portfolio, designed for use in risk prediction for progressive kidney function decline in type 2 diabetes patients with chronic kidney disease stages 1-3b.</p><p>The tests will be processed at a Renalytix laboratory and the tests' insights will be used for making changes in patient management, potentially helping healthcare providers improve key metrics in diabetes and kidney care and mitigate kidney function decline, the company said.</p><p>Tempus AI shares were up nearly 2% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Teams Up With Renalytix to Boost Adoption of Prognostic Blood Test for Kidney Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Teams Up With Renalytix to Boost Adoption of Prognostic Blood Test for Kidney Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-15 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) has formed a partnership with Renalytix to boost adoption of the kidneyintelX.dkd prognostic blood test for eligible patients who have type 2 diabetes with chronic kidney disease, Renalytix said Monday.</p><p>Renalytix said its kidneyintelX.dkd will be the first chronic kidney disease test in Tempus' portfolio, designed for use in risk prediction for progressive kidney function decline in type 2 diabetes patients with chronic kidney disease stages 1-3b.</p><p>The tests will be processed at a Renalytix laboratory and the tests' insights will be used for making changes in patient management, potentially helping healthcare providers improve key metrics in diabetes and kidney care and mitigate kidney function decline, the company said.</p><p>Tempus AI shares were up nearly 2% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4611","symbol_name":"AI医疗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2567149401","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567149401","pubTimestamp":1757940745,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tempus AI  has formed a partnership with Renalytix to boost adoption of the kidneyintelX.dkd prognostic blood test for eligible patients who have type 2 diabetes with chronic kidney disease, Renalytix said Monday.Renalytix said its kidneyintelX.dkd will be the first chronic kidney disease test in Tempus' portfolio, designed for use in risk prediction for progressive kidney function decline in type 2 diabetes patients with chronic kidney disease stages 1-3b.The tests will be processed at a Renalytix laboratory and the tests' insights will be used for making changes in patient management, potentially helping healthcare providers improve key metrics in diabetes and kidney care and mitigate kidney function decline, the company said.Tempus AI shares were up nearly 2% in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4611":"AI医疗","BK4121":"生命科学工具和服务","BK7095":"多种金属与采矿","TEM.AU":"TEMPEST MINERALS LTD","TEM":"Tempus AI","BK4613":"AI应用软件","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD"},"translate_title":"Tempus AI与Renalytix合作推动肾脏疾病预后血液检测的采用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM.AU":1,"TEM":1},"content_text":"Tempus AI (TEM) has formed a partnership with Renalytix to boost adoption of the kidneyintelX.dkd prognostic blood test for eligible patients who have type 2 diabetes with chronic kidney disease, Renalytix said Monday.Renalytix said its kidneyintelX.dkd will be the first chronic kidney disease test in Tempus' portfolio, designed for use in risk prediction for progressive kidney function decline in type 2 diabetes patients with chronic kidney disease stages 1-3b.The tests will be processed at a Renalytix laboratory and the tests' insights will be used for making changes in patient management, potentially helping healthcare providers improve key metrics in diabetes and kidney care and mitigate kidney function decline, the company said.Tempus AI shares were up nearly 2% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}